Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer - Summary - MDSpire
Advertisement
Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer
To evaluate the predictive value of hematological markers for pathologic response to neoadjuvant immunochemotherapy (NICT) in locally advanced gastric cancer (LAGC) and explore the impact of treatment cycle number on efficacy.
Key Findings:
Pre-treatment neutrophil count (Neutrophil_pre) and post-treatment albumin (ALB_post) are independent protective factors for MPR.
Post-treatment platelet count (PLT_post) is an independent risk factor for MPR.
The optimal pre-treatment neutrophil cutoff was determined to be 3.39×10^9/L.
Patients with pre-treatment neutrophils <3.39×10^9/L showed higher MPR and pathologic complete response rates with 4 cycles of therapy compared to 2-3 cycles.
Interpretation:
The study identifies specific hematological parameters that can predict pathologic response to NICT in LAGC, suggesting that treatment cycle adjustments may enhance outcomes for certain patient subgroups.
Limitations:
The study is retrospective and conducted at a single center, which may limit generalizability.
The control cohort receiving chemotherapy alone did not show the same associations, indicating potential differences in treatment responses.
Conclusion:
Pre-treatment neutrophil count, post-treatment platelet count, and post-treatment albumin level are independent predictors of pathologic response to NICT in LAGC, with implications for treatment cycle adjustments.
